Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GHZ339
- Development stage
- Phase 2
- Lead developer
- Novartis
- Administration
- Subcutaneous
01
Overview
GHZ339 is an investigational biological therapy under development by Novartis for the treatment of moderate to severe atopic dermatitis. It is currently classified as a new molecular entity and is being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase II platform trial. GHZ339 is grouped pharmacologically as an anti-inflammatory and skin disorder therapy, but its precise mechanism of action has not been publicly defined. There are no published details on its molecular target, structure, or specific pathway of action as of the latest available data[1][2][3][5][9].
- Other names
- GHZ339GHZ-339GHZ 339
Beyond the preview
Go deeper on GHZ339.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GHZ339.